Besides, among four major driver genes for PAAD, the high-risk group had a higher frequency of mutation in KRAS, and CDKN2A. KRAS and CDKN2A mutation and alterations are early events in the development of pancreatic tumors [29]. The gene discussed is CDKN2A; the disease is pancreatic neoplasm.